<?xml version="1.0" encoding="UTF-8"?>
<p id="p0320">
 <list list-type="simple" id="ulist0060">
  <list-item id="u0180">
   <label>•</label>
   <p id="p0325">In patients with decompensated cirrhosis, treatment for cirrhosis-associated complications such as portal hypertension, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis 
    <italic>etc.</italic> should be continued.
   </p>
  </list-item>
  <list-item id="u0185">
   <label>•</label>
   <p id="p0330">In patients with HCC, locoregional therapies should be postponed whenever possible and immune-checkpoint inhibitor therapy temporarily withdrawn. The decision on whether to continue (reduced dose) kinase inhibitors in non-severe COVID-19 should be taken on a case-by-case basis.</p>
  </list-item>
  <list-item id="u0190">
   <label>•</label>
   <p id="p0335">In patients after liver transplantation, dose adjustment of calceurin- and/or mTOR- inhibitors might be required depending on the antiviral therapy initiated (
    <xref rid="tbl1" ref-type="table">Table 1</xref>).
   </p>
  </list-item>
 </list>
</p>
